Please stop back for additional upcoming events. Thank you for your interest.
Neos Therapeutics Announces Issuance of Key Patent Covering its Extended Release Oral Disintegrating Tablet (XR-ODT) Platform Technology
Neos Therapeutics, Inc. Announces Settlement of Pending Patent Litigation Concerning its Amphetamine Polistirex XR-ODT (NT-0202) with Shire LLC
Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.
Neos Therapeutics Announces Positive Phase 3 Study Results for its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) in ADHD Patients
Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer
Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products: US Patent No. 8,709,491 will Provide Protection Until 2032
Neos Therapeutics Announces $20 Million Loan Facility and Updated Total of $18 Million for its Additional Series C Financing
Neos Therapeutics Completes $15.5 Million Additional Series C Financing